The investigators identified three cancer-testis antigens, as targets for cancer vaccination
against lung cancer. In this clinical study, the investigators examine using a combination of
three peptides from these three antigens (S-488410) the safety, immunogenicity, and antitumor
effect of vaccine treatment for advanced non-small cell lung cancer patients.